However, a recent meta-analysis reported no significant differences in the sex distribution, age at onset, initial symptoms, motor symptoms, depression, levodopa-equivalent dose, and related complications between LRRK2 G2385R-carrier and LRRK2 G2385R-noncarrier PD patients. This evidence concerns the gene LRRK2 and depressive symptom measurement.